IDH1 and Dravet syndrome: Both IDH inhibitors are associated with development of differentiation syndrome (DS), which is reported in approximately 12–15% of patients receiving an IDH inhibitor as monotherapy and is most frequently manifested as dyspnea, culture-negative fevers, pulmonary infiltrates, and/or hypoxia34.